Access to the PPM Journal and newsletters is FREE for clinicians.

Fibromyalgia: Addressing Co-morbidities, Part 2

Dealing with Depression and Functional Limits

Learn more about addressing fibromyalgia co-morbidities: Part 1 of this video covered sleep apnea and endocrine abnormalities. Part 2 will focus mainly on the psychological effects of fibromyalgia.

Depression and anxiety are common in fibromyalgia patients, and this video stresses the importance of treating those psychological effects as part of an overall fibromyalgia treatment plan.

Joseph Shurman, MD moderates this video, and he is the Chairman of Pain Management at Scripps Memorial Hospital in La Jolla, CA.

The panelists are:

  • Charles E. Argoff, MD: Professor of Neurology at Albany Medical College and Director or the Comprehensive Pain Center at Albany Medical Center
  • John F. Peppin, DO, FACP: Director, Clinical Research Division at The Pain Treatment Center of the Bluegrass
  • Steven P. Stanos, DO: Assistant Professor in Physical Medicine and Rehabilitation at Northwestern University Feinberg School of Medicine and Medical Director, Center for Pain Management at the Rehabilitation Institute of Chicago

The panelists discuss antidepressants to consider, as well as the complexity of treating depression in fibromyalgia patients. As Dr. Stanos points out, often depression (or other psychological effects) need to be treated before general fibromyalgia treatment can be as effective as possible.

The panel also addresses how to deal with patients who are functionally limited. Dr. Peppin brings up using the 6-minute walk test in your clinic, which is something he has done with success in his own practice. You can read more about this in his poster presenting research on assessing functional status in the chronic pain patient.

Last updated on: April 27, 2012
close X